Lineage Cell Therapeutics (LCTX) Non-Current Deffered Revenue (2010 - 2026)

Lineage Cell Therapeutics has reported Non-Current Deffered Revenue for 16 years, with the latest figure at $13.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 4.5% year-over-year to $13.0 million; the trailing twelve-month figure through Mar 2026 stood at $13.0 million (down 4.5% YoY), and the FY2025 full-year result was $12.4 million, down 14.25% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $13.0 million, up from $12.4 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $30.8 million in Q1 2022, with the low at $12.4 million in Q4 2025.
• Historically, Non-Current Deffered Revenue has averaged $19.3 million across 5 years, with a median of $18.5 million in 2024.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue plunged 32.58% — and 2026, when it decreased 4.5%.
• Lineage Cell Therapeutics' Non-Current Deffered Revenue stood at $27.7 million in 2022, then tumbled by 32.58% to $18.7 million in 2023, then decreased by 22.79% to $14.4 million in 2024, then slipped by 14.25% to $12.4 million in 2025, then gained by 5.03% to $13.0 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $13.0 million (Q1 2026), $12.4 million (Q4 2025), and $12.5 million (Q3 2025), per Business Quant data.